Can a new drug shrink Hard-to-Treat tumors?
NCT ID NCT07767474
First seen Aug 17, 2026 · Last updated Aug 17, 2026
Summary
This study tests an experimental drug called ATX-898 in people with advanced solid tumors that have spread or cannot be removed by surgery. The trial has two parts: first, ATX-898 is given alone to find the safest dose; second, it is combined with other anti-cancer drugs to see if that works better. The main goals are to check safety and tolerability, and to see if the drug causes tumors to shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ATX-898, an experimental drug, given alone or combined with other anti-cancer agents (fulvestrant, ribociclib, abemaciclib)
- What this could lead to
- If successful, this could lead to a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
- What could go wrong
- This is an early-phase trial, so the drug may not be safe or effective. Side effects are possible, and the benefits are not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.